Ropeginterferon alfa-2b Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ropeginterferon alfa-2b comprises 9 peer-reviewed publications across 8 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Myeloproliferative Disorders, Polycythemia Vera, COVID-19, and Primary Myelofibrosis. Most recent publication: Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction., Blood Adv, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Verstovsek S, Komatsu N, Gill H, et al. · Future Oncol · 2022
    PubMed: PMID 35924546 · NCT04285086 (SURPASS ET) · Myeloproliferative Disorders
  2. Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.
    Qin A, Shimoda K, Suo S, et al. · Pharmacol Res Perspect · 2025
    PubMed: PMID 40313042 · NCT03546465
  3. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.
    Mesa R, Gill H, Zhang L, et al. · Lancet Haematol · 2025
    PubMed: PMID 41193116 · NCT04285086 (SURPASS ET) · Myeloproliferative Disorders
  4. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
    Masarova L, Reeves BN, El Chaer F, et al. · Front Med (Lausanne) · 2025
    PubMed: PMID 40330782 · NCT05482971 · Myeloproliferative Disorders
  5. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
    Liu WD, Hou HA, Li KJ, et al. · Adv Ther · 2024
    PubMed: PMID 38010606 · NCT05808322 · COVID-19
  6. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
    Jin J, Zhang L, Qin A, et al. · Exp Hematol Oncol · 2023
    PubMed: PMID 37344895 · NCT05485948 · Polycythemia Vera
  7. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J, Qin A, Zhang L, et al. · Future Oncol · 2023
    PubMed: PMID 37129584 · NCT05485948 · Polycythemia Vera
  8. Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.
    Gill H, Au L, Yim RLH, et al. · Blood Adv · 2026
    PubMed: PMID 41875235 · NCT04988815 · Primary Myelofibrosis

Publications by year

2021–2026: 9 publications.

2021
1
2022
1
2023
2
2024
1
2025
3
2026
1

Publications by indication

Myeloproliferative Disorders (3)

  • Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.
    Lancet Haematol · 2025 · PMID 41193116 · NCT04285086
  • A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
    Front Med (Lausanne) · 2025 · PMID 40330782 · NCT05482971
  • SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Future Oncol · 2022 · PMID 35924546 · NCT04285086

Polycythemia Vera (2)

  • A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
    Exp Hematol Oncol · 2023 · PMID 37344895 · NCT05485948
  • A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Future Oncol · 2023 · PMID 37129584 · NCT05485948

COVID-19 (1)

  • Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
    Adv Ther · 2024 · PMID 38010606 · NCT05808322

Primary Myelofibrosis (1)

  • Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.
    Blood Adv · 2026 · PMID 41875235 · NCT04988815

Publications by journal

All Ropeginterferon alfa-2b publications (9)

2026 (1 paper)

  1. Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.
    Gill H, Au L, Yim RLH, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41875235 · NCT04988815 · Primary Myelofibrosis

2025 (3 papers)

  1. Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.
    Qin A, Shimoda K, Suo S, et al. · Pharmacol Res Perspect · 2025 · Derived
    PubMed: PMID 40313042 · NCT03546465
  2. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.
    Mesa R, Gill H, Zhang L, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 41193116 · NCT04285086 (SURPASS ET) · Myeloproliferative Disorders
  3. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
    Masarova L, Reeves BN, El Chaer F, et al. · Front Med (Lausanne) · 2025 · Derived
    PubMed: PMID 40330782 · NCT05482971 · Myeloproliferative Disorders

2024 (1 paper)

  1. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
    Liu WD, Hou HA, Li KJ, et al. · Adv Ther · 2024 · Derived
    PubMed: PMID 38010606 · NCT05808322 · COVID-19

2023 (2 papers)

  1. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
    Jin J, Zhang L, Qin A, et al. · Exp Hematol Oncol · 2023 · Derived
    PubMed: PMID 37344895 · NCT05485948 · Polycythemia Vera
  2. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J, Qin A, Zhang L, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 37129584 · NCT05485948 · Polycythemia Vera

2022 (1 paper)

  1. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Verstovsek S, Komatsu N, Gill H, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35924546 · NCT04285086 (SURPASS ET) · Myeloproliferative Disorders

2021 (1 paper)

  1. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N, Zagrijtschuk O, Kang L, et al. · Clin Drug Investig · 2021 · Derived
    PubMed: PMID 33725322 · NCT03546465

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).